All In MedTech

FDA Clearance Tracker · P130013-S001

WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 21, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 21, 2016

Approved

Time to decision

591 days

Received Apr 10, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130013-S001
Device name
WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY
Applicant location
Maple Grove, MN
Received
Apr 10, 2015
Decided
Nov 21, 2016
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P130013

Device type

Device class
Class III

Every decision under product code NGV

FDA's approval statement

As written in FDA's record.

Approval to modify the post-approval study (PAS) condition of approval.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.